cefepime (maxipeme) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cefepime is a fourth-generation cephalosporin antibiotic, which was developed in 1994. Cefepime has a broad spectrum in vitro activity that encompasses a wide range of Gram-positive and Gram-negative bacteria. Within bacterial cells, the molecular targets of cefepime are the penicillin binding proteins (PBP). It is FDA approved for the treatment of pneumonia, febrile neutropenia, uncomplicated UTI, uncomplicated skin infection and complicated intraabdominal infections. Common adverse reactions include rash, hypophosphatemia, diarrhea. Cefepime is metabolized to N-methylpyrrolidine (NMP) which is rapidly converted to the N-oxide (NMP-N-oxide). Urinary recovery of unchanged cefepime accounts for approximately 85% of the administered dose. Less than 1% of the administered dose is recovered from urine as NMP, 6.8% as NMP-N-oxide, and 2.5% as an epimer of cefepime. Because renal excretion is a significant pathway of elimination, patients with renal dysfunction and patients undergoing hemodialysis require dosage adjustment.   NCATS

Chemistry

  • SMILES: CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)[O-])C[N+]3(C)CCCC3)\c4csc(N)n4
  • InChIKey: HVFLCNVBZFFHBT-ZKDACBOMSA-N
  • Mol. Mass: 480.57
  • ALogP: -1.28
  • ChEMBL Molecules:
    cefepime  
    cefepime hydrochloride  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$3.1090 - $5.3961

United States

$12.2092 - $18.1292
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(6r,7r)-7-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | axépim | bmy 28142 | bmy-28142 | bristol-myers brand of cefepime dihydrochloride | bristol-myers squibb brand of cefepime dihydrochloride | cefepim | cefepima | cefepime | cefepime dihydrochloride hydrate | cefepime hcl | cefepime hydrochloride | cefepime hydrochloride (arginine formulation) | cefepimum | cefimen | elan brand of cefepime dihydrochloride | maxipeme | maxipime | pyrrolidinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-, hydroxide, inner salt, (6r-(6alpha,7beta(z)))- | quadrocef | tsefepim | zidebactam

Organizations (87)

Research & Development (77)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (70)

Approved Indications (5)


 

Febrile Neutropenia (approved 1996)

Intraabdominal Infections (approved 1996)

Pneumonia

Skin Diseases, Bacterial (approved 1996)

Urinary Tract Infections (approved 1996)

Experimental Indications - Clinical Trial Phases 1-4 (68)


 

Antibiotic Prophylaxis (Phase 4)

Bacteremia (Phase 4)

Bacterial Infections (Phase 1)

Breast Neoplasms (Phase 1)

Burkitt Lymphoma (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 1)

Cesarean Section (Phase 2/Phase 3)

Community-Acquired Infections (Phase 3)

Cross Infection (Phase 3)

Cystic Fibrosis (Phase 4)

Drug-Related Side Effects and Adverse Reactions (Phase 1)

Endocarditis (Phase 4)

Enterobacteriaceae Infections (Phase 3)

Febrile Neutropenia (Phase 4)

Fever (Phase 3)

Gastrointestinal Microbiome (Phase 2)

Gram-Positive Bacterial Infections (Phase 3)

Hamartoma (Phase 4)

Healthy Volunteers (Phase 1)

Hodgkin Disease (Phase 1)

Infections (Phase 3)

Kidney Diseases (Phase 1)

Kidney Failure, Chronic (Phase 1)

Leukemia (Phase 4)

Leukemia, Eosinophilic, Acute (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 1)

Leukemia, Myelomonocytic, Chronic (Phase 1)

Leukemia, Neutrophilic, Chronic (Phase 1)

Leukemia, Prolymphocytic (Phase 1)

Lymphoma (Phase 4)

Lymphoma, B-Cell, Marginal Zone (Phase 1)

Lymphoma, Follicular (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Lymphoma, Large-Cell, Immunoblastic (Phase 1)

Lymphoma, Mantle-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Multiple Myeloma (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Myeloproliferative Disorders (Phase 1)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 3)

Neoplasms, Plasma Cell (Phase 1)

Neuroblastoma (Phase 1)

Neutropenia (Phase 3)

Osteomyelitis (Phase 2)

Ovarian Neoplasms (Phase 1)

Pharmacokinetics (Phase 1)

Pneumonia (Phase 4)

Pneumonia, Aspiration (Phase 4)

Pneumonia, Bacterial (Phase 3)

Pneumonia, Ventilator-Associated (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Primary Myelofibrosis (Phase 1)

Pseudohypoaldosteronism (Phase 1)

Pseudomonas aeruginosa (Phase 2)

Pseudomonas Infections (Phase 3)

Pyelonephritis (Phase 3)

Respiratory Aspiration (Phase 4)

Respiratory Tract Infections (Phase 3)

Sepsis (Phase 4)

Sezary Syndrome (Phase 1)

Shock, Septic (Phase 3)

Testicular Neoplasms (Phase 1)

Urinary Tract Infections (Phase 3)

Wound Infection (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 54
  • # of Trial Organizations: 77

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue